MarketBeat
09 Aug 2026, 00:05 UTC · 2h ago
Prestige Consumer Healthcare Q1 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
09 Aug 2026, 00:05 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Prestige Consumer Healthcare raised its full-year revenue and free cash flow outlooks following the acquisitions of Breathe Right and LaCorium Health. — Upward revisions to top-line and cash flow guidance typically drive positive share price reactions.
+0.60The Breathe Right acquisition is expected to generate approximately $200 million in annual revenue and provide about $0.25 of annualized EPS accretion. — Direct EPS accretion provides a concrete catalyst for valuation growth.
+0.40The company reached a record quarterly adjusted free cash flow of $83.7 million, raising its full-year expectation to at least $270 million. — Strong cash flow generation supports debt repayment and capital allocation flexibility.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Supply constraints for Clear Eyes will continue to cause output variability through the first half of fiscal 2027. — Ongoing operational headwinds in a specific product line create a short-term drag on performance, though the brand is a small portion of total sales.
-0.20Prestige successfully extended its debt maturity profile, with the earliest maturity now pushed to 2031. — Reducing immediate refinancing risk improves the company's credit profile and long-term stability.
+0.20Which stocks this story touches
Reported revenue and EPS growth, record free cash flow, and raised its full-year outlook following strategic acquisitions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
The Motley Fool
1h ago
